MEI Pharma, Inc.

MEIPNASDAQHealthcare

$3.07

+$0.29(+10.43%)

Market Cap$20452012

P/E Ratio—

52W High$9

52W Low$1.46

Avg Volume1.5M

Open$2.89

Beta0.22

Free Cash Flow Financials Revenue

MEI Pharma, Inc. (MEIP) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

MEIP · free cash flow · updated Jun 9, 2026

Core FCF metrics

MEIP · FCF · TTM · margin & CAGR

Free cash flow was −$20.8M for FY2025 (fiscal year ending 2025-06-30), up 58.7% year-over-year

FY2025 Free Cash Flow−$20.8M▲ +58.7% YoY

Trailing 12M (TTM)−$10.4Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

MEIP · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$20.8M(0M)−$20.8M▲ +58.7%—

FY2024−$50.5M(0M)−$50.5M▲ +3.9%-77.3%

FY2023−$52.5M(0M)−$52.5M▼ 6.7%-107.6%

FY2022−$48.7M(0M)−$49.2M▼ 50.7%-121.0%

FY2021−$32.0M(1M)−$32.7M▼ 197.9%-128.0%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

MEIP · P/FCF · FCF yield · FCF per share

MEI Pharma, Inc. (MEIP) reported negative free cash flow of −$0.02B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-06-30

Cash flow statement summary

MEIP · cash flow statement · operating / investing / financing

For FY2025, MEI Pharma, Inc. generated −$20.8M in operating cash flow and spent 0M in capital expenditures, yielding −$20.8M in free cash flow.

Operating Activities

−$20.8M

Cash from core business operations

2025-06-30

Investing Activities

+$35.1M

CapEx, acquisitions & investments

2025-06-30

Financing Activities

+$0.0M

Buybacks, dividends & debt

2025-06-30

FCF FormulaOperating CF (−$20.8M) − |CapEx| (0M) = FCF (−$20.8M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

MEIP vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

MEI Pharma, Inc.YOU

MEIP

−$20.8M+58.7%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

MEI Pharma, Inc. (MEIP) reported free cash flow of −$20.8M for FY2025 (fiscal year ending 2025-06-30), up 58.7% year-over-year.

Based on available data, MEI Pharma, Inc. has maintained positive free cash flow for at least 2 fiscal year(s). FCF peaked at $33.4M in FY2020.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

MEIP free cash flow · 8 questions

MEI Pharma, Inc. free cash flow was −$20.8M for FY2025, up 58.7% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$10.4M.

MEIP free cash flowMEIP FCFMEIP FCF 2025MEIP free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · MEI Pharma, Inc. · MEI Pharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026